Lustro Comments

Discuss this Deal with other Investors

Join the Conversation

InvVax

We use a new genetics platform to develop better vaccines for flu, COVID-19, etc

Print
Follow Claim My Business
Form C
View on Wefunder
Security Type
Convertible Note
Categories
Technology, Community & Lifestyle, Healthcare & Medical, Education
Min Investment
$100
Location
Pasadena, CA
Expected Close Date
April 29, 2024
Target Raise
$50.00K-$1.24M
No. Investors
135
Security Price
$1
Website
inv-vax.com
Number of Employees
1
Cash
$78,101
Revenue
$0
Short Term Debt
$868,273
Cost of Goods
$0
Long Term Debt
$0
Net Income
$-120,932

Key Deal Facts

Huge global market for these vaccines: Universal flu - $22B; COVID-19 - $5B Chance to make an enormous societal impact Patented durable and universal flu vaccine Major smashes: Moderna, BioNTech, Novavax: Invest in the next one! Backed by Life Science Angels - #1 US angel group (CB Insights), Sand Hill Angels, Tech Coast Angels Funded by the DoD and the NSF

Management Team / Advisory Board Bios

Arthur Young CEOPhD from a top 5-medical school, postdocs at Harvard and UCLA, pioneered a powerful new viral genetics platform, Olga Petrauskene DirectorProduced an HIV and flu diagnostic with Applied Biosystems that is sold in 60 countries, Justin Kern DirectorWrote a freelance article for Newsweek on vaccines that reached millions

Amount Raised : $129,283
Reveal the Score by Voting
＿
0
ⓘ
Business Idea
ⓘ
Business Traction
ⓘ
Management Team
ⓘ
Valuation

Security Description

A convertible security is a security that can be converted into another security, typically equity in the next round of financing.

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment